Androgen Deprivation therapy for Oligo-recurrent Prostate cancer in addition to radioTherapy (ADOPT): study protocol for a randomised phase III trial

Androgen Deprivation therapy for Oligo-recurrent Prostate cancer in addition to radioTherapy (ADOPT): study protocol for a randomised phase III trial

Abstract Background More than 60% of oligo-recurrent prostate cancer (PCa) patients treated with metastasis-directed radiotherapy (MDRT) develop biochemical recurrence within 2 years. This recurrence rate emphasises the need for improved treatment and patient selection. In line with the treatment of...

Full description

Bibliographic Details
Main Authors: J. Janssen, F. H. E. Staal, C. L. Brouwer, J. A. Langendijk, I. J. de Jong, R. J. A. van Moorselaar, E. Schuit, J. F. Verzijlbergen, R. J. Smeenk, S. Aluwini
Format: Article
Language:English
Published: BMC 2022-05-01
Series:BMC Cancer
Subjects:
Oligometastasis
Recurrence
Prostate Cancer
MDRT
SBRT
ADT
Online Access:https://doi.org/10.1186/s12885-022-09523-2

Internet

https://doi.org/10.1186/s12885-022-09523-2

Similar Items